1398705-08-2

Upstream product

• 177947-96-5 tert-butyl 3-formylazetidine-1-carboxylate 
• 348-61-8 1-bromo-3,4-difluorobenzene 
• 142253-56-3 3-hydroxymethyl-azetidine-1-carboxylic acid tert-butyl ester 
• 142253-55-2 1-(t-butyloxycarbonyl)-azetidine-3-carboxylic acid 
• 90897-92-0 3,4-difluorophenylmagnesium bromide 

Downstream Products

• 1398706-60-9 C₂₁H₂₂ClF₂NO₃ 

Relevant academic research and scientific papers

NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION

The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders.

Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors

Novel azetidines based on the 3-aryl-3-oxypropylamine scaffold were designed, synthesized, and evaluated as TRIs. Reduction of 1 followed by Swern oxidation and then Grignard reaction gave 3. The alkylation of 3 provided the corresponding azetidine derivatives 6, of which the two most promising, 6bd and 6be, were selected from 86 prepared analogues based on their biological profiles. Compound 6be showed activity in vivo in FST at 10 mg/kg IV or 20-40 mg/kg PO.